Opening book details…
Can I read The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: Hype or hope? on EtoBox?
The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: Hype or hope? by Michael Trauner is a Medicine article available to read on EtoBox.
What is The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: Hype or hope? about?
Farnesoid X receptor (FXR) is a bile acid-activated transcription factor that is a member of the nuclear hormone receptor superfamily. FXR-null mice exhibit a phenotype similar to Byler disease, an inherited cholestatic liver disorder. In the liver, activation of FXR induces transcription of transporter genes involved in promoting bile acid clearance and represses genes involved in bile acid biosynthesis. We investigated whether the synthetic FXR agonist GW4064 could protect against cholestatic liver damage in rat models of extrahepatic and intrahepatic cholestasis. In the bile duct ligation and alpha-naphthylisothiocyanate models of cholestasis, GW4064 treatment resulted in significant reductions in serum alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase, as well as other markers of liver damage. Rats that received GW4064 treatment also had decreased incidence and extent of necrosis, decreased inflammatory cell infiltration, and decreased bile duct proliferation. Analysis of gene expression in livers from GW4064-treated cholestatic rats revealed decreased expression of bile acid biosynthetic genes and increased expression of genes involved in bile aci
Who reads The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: Hype or hope??
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Michael Trauner
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Published
- 2004
- Language
- EN
- Field
- Medicine (Health Sciences)